CRIS Earnings

CRIS reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 3.18M against an estimate of 2.86M, resulting in a 11.05% surprise. The EPS was -0.49, surpassing the expected -0.62 by 20.97%. The stock experienced a -10.27% price change on the earnings day and a -15.75% change over the next five days, reflecting market reactions to the results.

Following CRIS's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by -10.27% on the day of the release. Over the subsequent five days, it saw a -15.75% change. Historically, CRIS's stock price tends to shift by an average of 9.7% in the 10 days leading up to earnings and -8.42% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate CRIS's annual revenue to reach 3.00M, while the EPS is projected at -0.30. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CRIS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CRIS's stock price typically moves by 9.7% in the 10 days before its earnings and -8.42% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.30 and revenue of 3.00M.

The earnings call reveals a mixed picture. While there is a positive net income due to a one-time gain, the company faces ongoing financial losses and operational risks. The lack of revenue for 2026 and dependence on future financing are concerns. However, the optimistic guidance for clinical trials and reduced expenses are positive. The Q&A session highlights challenges in trial enrollment and management's reluctance to provide specifics, adding uncertainty. Given these factors, the stock price is expected to remain stable in the short term, leading to a neutral sentiment rating.